Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Mitochondrial Metabolism as a Therapeutic Target for Relapsed B-cell Acute Lymphoblastic Leukemia
FY 2020-21
Summary
Acute Lymphoblastic leukemia (ALL) is a cancer of the blood characterized by an increase in white blood cells in the blood and bone marrow. This malignancy affects one to five per 100,000 persons per year, worldwide. B-cell ALL (B-ALL) is the most common type of ALL. Relapse- a return of cancer after a cancer free period, will occur in 15-20% of pediatric and 40-70% of adult patients. Upon relapse survival is poor. Relapse B-ALL cells are more dependent upon metabolism of mitochondria, the energy factory of the cell, than diagnosis cells. This suggests that targeting mitochondrial metabolism could provide a means of targeting therapy resistant relapse cells and diagnosis cells which are destined to become therapy resistant. To test this, I will carry out three aims. Aim one, profile the mitochondrial metabolism of diagnosis, relapse-fated, and relapse samples, with the SeaHorse metabolism assay. Aim two, utilize a variety of computational approaches to identify unique properties of relapse and relapse-fated cells, which will identify the unique vulnerabilities of these cells. Aim three, target the vulnerabilities of relapse and relapse-fated cells, identified in aims one and two, and assess their sensitivity to standard chemotherapy treatment. I will use the gene editing technique, CRISPR, to eliminate the function of important genes in chemotherapy resistance, following which, I will assess sensitivity to standard chemotherapy treatment. I will identify candidate drugs by treating relapse cells with drugs targeting their vulnerabilities and assess their sensitivity to standard chemotherapy treatment. Significance: By targeting mitochondrial metabolism, my project will identify new therapeutic targets for B-ALL and potentially improve the cure rates of relapsed B-ALL.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449447
Name
Smith Sabrina A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Mitochondrial Metabolism as a Therapeutic Target for Relapsed B-cell Acute Lymphoblastic Leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
B-Cell Acute Lymphoblastic Leukemia; Chemoresistance; Chemotherapy; Leukemia; Metabolism; Mitochondria; Relapse; Therapeutics
Abstract
Acute Lymphoblastic leukemia (ALL) is a cancer of the blood characterized by an increase in white blood cells in the blood and bone marrow. This malignancy affects one to five per 100,000 persons per year, worldwide. B-cell ALL (B-ALL) is the most common type of ALL. Relapse- a return of cancer after a cancer free period, will occur in 15-20% of pediatric and 40-70% of adult patients. Upon relapse survival is poor. Relapse B-ALL cells are more dependent upon metabolism of mitochondria, the energy factory of the cell, than diagnosis cells. This suggests that targeting mitochondrial metabolism could provide a means of targeting therapy resistant relapse cells and diagnosis cells which are destined to become therapy resistant. To test this, I will carry out three aims. Aim one, profile the mitochondrial metabolism of diagnosis, relapse-fated, and relapse samples, with the SeaHorse metabolism assay. Aim two, utilize a variety of computational approaches to identify unique properties of relapse and relapse-fated cells, which will identify the unique vulnerabilities of these cells. Aim three, target the vulnerabilities of relapse and relapse-fated cells, identified in aims one and two, and assess their sensitivity to standard chemotherapy treatment. I will use the gene editing technique, CRISPR, to eliminate the function of important genes in chemotherapy resistance, following which, I will assess sensitivity to standard chemotherapy treatment. I will identify candidate drugs by treating relapse cells with drugs targeting their vulnerabilities and assess their sensitivity to standard chemotherapy treatment. Significance: By targeting mitochondrial metabolism, my project will identify new therapeutic targets for B-ALL and potentially improve the cure rates of relapsed B-ALL.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Smith, Sabrina A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~